Literature DB >> 501796

Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus.

L G Payne.   

Abstract

HeLa, SIRC, and RK-13 cells were compared as to their production of intracellular naked vaccinia virus (INV) and extracellular enveloped vaccinia virus (EEV) after infection with vaccinia strains WR and IHD-J. IHD-J produced more EEV from all three cell lines than did WR, although both strains produced approximately the same quantity of INV. The most efficient EEV release was from RK-13 cells infected with IHD-J, which was 200 times more than from WR-infected SIRC cells. This permitted for the first time the purification of milligram quantities of EEV that contained much fewer cell protein contaminants than could be obtained from HeLa or SIRC cells. The INV surface proteins 200K, 95K, 65K, and 13K were present in both HeLa and RK-13 cell-derived INV but were absent in SIRC cell INV. These proteins were absent in EEV from all three cell lines. Four glycoproteins of molecular weights 210 x 10(3) (210K), 110K, 89K, and 42K and five glycoproteins in the 23K to 20K range plus a nonglycosylated protein of 37K were detected in EEV from the hemagglutinin-positive IHD-J vaccinia strain. The 89K glycoprotein was not present in EEV or membranes from cells infected with the hemagglutinin-negative vaccinia strain IHD-W. Antisera to IHD-W lacking hemagglutinin-inhibiting antibodies did not precipitate the 89K glycoprotein of IHD-J. The only glycoprotein that specifically attached to rooster erythrocytes was the 89K glycoprotein. This evidence indicates that the 89K glycoprotein is the vaccinia hemagglutinin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 501796      PMCID: PMC353430     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  GIANT CELL FORMATION IN L CELLS INFECTED WITH ACTIVE VACCINIA VIRUS.

Authors:  H KAKU; J KAMAHORA
Journal:  Biken J       Date:  1964-01

2.  Biogenesis of vaccinia. Effects of inhibitors of glycosylation on virus-mediated activities.

Authors:  S Weintraub; W Stern; S Dales
Journal:  Virology       Date:  1977-05-01       Impact factor: 3.616

3.  An antigenic difference between intracellular and extracellular rabbitpox virus.

Authors:  G Appleyard; A J Hapel; E A Boulter
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

4.  Biogenesis of poxviruses: genetically controlled modifications of structural and functional components of the plasma membrane.

Authors:  S Weintraub; S Dales
Journal:  Virology       Date:  1974-07       Impact factor: 3.616

5.  Vaccinia-specific hemagglutinin.

Authors:  Y Ichihashi
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

6.  Evidence for a ninth influenza viral polypeptide.

Authors:  R A Lamb; P R Etkind; P W Choppin
Journal:  Virology       Date:  1978-11       Impact factor: 3.616

7.  A human lymphoid cell line with an IgG-like membrane component.

Authors:  K Nilsson; V Ghetie; J Sjöquist
Journal:  Eur J Immunol       Date:  1975-08       Impact factor: 5.532

8.  Polypeptide composition of extracellular enveloped vaccinia virus.

Authors:  L Payne
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

9.  Adsorption and penetration of enveloped and naked vaccinia virus particles.

Authors:  L G Payne; E Norrby
Journal:  J Virol       Date:  1978-07       Impact factor: 5.103

10.  Single radial immunodiffusion test for detecting antibodies against surface antigens of intracellular and extracellular vaccinia virus.

Authors:  V J Prakash; E Norrby; L Payne
Journal:  J Gen Virol       Date:  1977-06       Impact factor: 3.891

View more
  64 in total

1.  Using confocal microscopy to study virus binding and entry into cells.

Authors:  A Vanderplasschen; G L Smith
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

2.  Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication.

Authors:  F G da Fonseca; E J Wolffe; A Weisberg; B Moss
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein.

Authors:  Ehud Katz; Brian M Ward; Andrea S Weisberg; Bernard Moss
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

4.  Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway.

Authors:  Alan C Townsley; Andrea S Weisberg; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Role of cell-associated enveloped vaccinia virus in cell-to-cell spread.

Authors:  R Blasco; B Moss
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

6.  Association of vaccinia virus fusion regulatory proteins with the multicomponent entry/fusion complex.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

7.  Vaccinia virus strain differences in cell attachment and entry.

Authors:  Zain Bengali; Alan C Townsley; Bernard Moss
Journal:  Virology       Date:  2009-05-09       Impact factor: 3.616

8.  Fusion of intra- and extracellular forms of vaccinia virus with the cell membrane.

Authors:  R W Doms; R Blumenthal; B Moss
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

9.  Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene.

Authors:  R Blasco; J R Sisler; B Moss
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Authors:  Natasha M Girgis; Brian C Dehaven; Xin Fan; Kendra M Viner; Mohammad Shamim; Stuart N Isaacs
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.